The abstract is read at the publisher; the summary is JClub's.
CYP2D6 poor metaboliser status is linked to higher odds of venlafaxine treatment failure, with odds ratios up to 2·05 in the Norwegian cohort and 1·58 in UK Biobank.
- Why it matters: Venlafaxine’s response may vary because CYP2D6 and CYP2C19 metabolise it, but real-world evidence linking genotype-defined metabolism to switching away from venlafaxine has been limited.
- What they did: In two retrospective naturalistic cohorts (Oslo, Norway; UK Biobank), participants on venlafaxine were excluded if they used strong CYP2D6/CYP2C19 inhibitors or CYP inducers at last therapeutic drug monitoring, then stratified into predicted poor, intermediate, normal, and ultra-rapid metabolisers.
- The result: Switching within 1 year was more likely for CYP2D6 PMs versus normal metabolisers (Norway: OR 2·05, p<0·0001; UK Biobank: OR 1·58, p=0·0060), and dual CYP2D6/CYP2C19 PMs showed amplified risk in Norway (OR 6·11, p=0·0019).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.